Literature DB >> 8320961

The study of human neoplastic disease in severe combined immunodeficient mice.

S S Williams1, T R Alosco, B A Croy, R B Bankert.   

Abstract

Experimental models of human neoplastic diseases are used in attempts to reconstruct events that occur in patients with cancer. Although in vitro systems provide a wealth of information about the cellular and molecular biology of tumor cells, they are inadequate for studies that address the complexities of human neoplasia pertaining to metastasis, experimental therapeutics, and immunity. Since the late 1960s, athymic nude mice have provided an opportunity to study the growth and, in some cases, the metastasis of xenografted human tumors in vivo. Recently, the availability of severe combined immunodeficient (scid) mice has provided an alternative model for studying human malignancies and has led to numerous reports of its distinct advantages over nude mice. When direct comparisons have been made, it has often been apparent that human tumors grow better and are more likely to metastasize in scid mice than in nude mice. Indeed, some human tumors which have never before been propagated in vivo will engraft in scid mice. Furthermore, the unique capability of scid mice to support human immunocompetent cells offers the potential to study the human immune response to tumors. This article outlines the current progress toward defining and using scid mice in models of human neoplastic disease. Characteristics which distinguish scid mice from nude mice are emphasized and a discussion of future prospects is included.

Entities:  

Mesh:

Year:  1993        PMID: 8320961

Source DB:  PubMed          Journal:  Lab Anim Sci        ISSN: 0023-6764


  8 in total

1.  Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.

Authors:  Zeng B Zhu; Angel A Rivera; Sharmila K Makhija; Baogen Lu; Minghui Wang; Miiru Izumi; Robert J Cerfolio; Mariam A Stoff-Khalili; Fen Zhou; Koichi Takayama; Gene P Siegal; David T Curiel
Journal:  Lung Cancer       Date:  2006-11-17       Impact factor: 5.705

2.  Spontaneous nonthymic tumors in SCID mice.

Authors:  Peigen Huang; Susan V Westmoreland; Rakesh K Jain; Dai Fukumura
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

Review 3.  Human cancer growth and therapy in immunodeficient mouse models.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

4.  Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models.

Authors:  Diala Ghazal; Fatma Zalzala; John C Fisk; Swetha Tati; Loukia G Karacosta; Susan Morey; James R Olson; Sally Quataert; Grace K Dy; Kate Rittenhouse-Olson
Journal:  Oncotarget       Date:  2022-10-19

5.  Human villous adenomas engrafted into scid mice survive for prolonged period without malignant transformation.

Authors:  H L Bumpers; T R Alosco; H Q Wang; N J Petrelli; E L Hoover; R B Bankert
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 6.  Animal models of human-derived cancer vaccines.

Authors:  D Herlyn; R Somasundaram; W Li; L Jacob
Journal:  Cell Biophys       Date:  1995-08

7.  Evaluation of riboflavin photochemical treatment for inactivation of HCT116 tumor cells mixed in simulative intraoperative salvage blood.

Authors:  Yang Yu; Lu Yang; Chunyu He; Shengfei Tai; Chunya Ma; Tianxin Yang; Deqing Wang
Journal:  Transfusion       Date:  2019-09-30       Impact factor: 3.157

8.  Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.

Authors:  Nadine Aschmoneit; Lennart Kühl; Oliver Seifert; Roland E Kontermann
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.